Back to top

Press Releases

Zacks Equity Research

The Zacks Analyst Blog Highlights: VIVUS, Geron, Achillion Pharmaceuticals, Anika Therapeutics and ANI Pharmaceuticals

VVUS GERN ACHN ANIK ANIP

Trades from $3

For Immediate Release

Chicago, IL – October 05, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include VIVUS Inc. ( NASDAQ:(VVUS - Free Report) - Free Report ), Geron Corporation ( NASDAQ:(GERN - Free Report) - Free Report ), Achillion Pharmaceuticals, Inc. ( NASDAQ:(ACHN - Free Report) - Free Report ), Anika Therapeutics Inc ( NASDAQ:(ANIK - Free Report) - Free Report ) and ANI Pharmaceuticals, Inc. ( NASDAQ:(ANIP - Free Report) - Free Report ) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday’s Analyst Blog:

Biotech Mergers Run the Show: 5 Small-Caps for Q4

Healthcare merger and acquisition activity has gathered steam over the past few years. A few big mergers in the recent past include that of Pfizer and Wyeth, Pfizer and Hospira, Novartis AG and Alcon, Sanofi and Genzyme, Roche and Genentech, and AstraZeneca and MedImmune. Consolidation helps large pharma companies gain more pricing power while simultaneously curbing competition.

Last November, Pfizer announced that it would acquire Allergan for $160 billion. However, this deal fell apart in Apr 2016 due to the new U.S. tax inversion rules.

There has been a flurry of mergers and acquisitions in the healthcare space this year too. In August, Pfizer announced the acquisition of oncology-focused Medivation for approximately $14 billion. The deal is expected to close this year. This was preceded by the buyout of Anacor in Jun 2016.

Also in June, Shire acquired Baxalta to brace its rare disease portfolio further, while Aegerion Pharmaceuticals and QLT entered into a definitive merger agreement to form a new company, Novelion Therapeutics Inc.

In April, Abbott Laboratories announced plans to buy St. Jude Medical in a move to bolster its share in the cardiovascular device market. In fact, the month of September probably saw higher merger/acquisition activity this year. Horizon Pharma announced plans to buy California-based Raptor Pharmaceuticals. This acquisition, slated to close in the fourth quarter, is likely to strengthen Horizon’s orphan business in the U.S. and expand it in Europe and key important markets.

After months of negotiations, German pharmaceutical maker, Bayer AG last month announced a definitive merger agreement to acquire Monsanto in an all-cash deal worth $66 billion.

Allergan announced a string of small bolt-on acquisitions last month. It announced a definitive deal to acquire Tobira Therapeutics, a clinical-stage biotechnology company focused on drugs to treat non-alcoholic steatohepatitis (NASH) and other liver diseases at a massive premium of 500%. Also, Allergan said it will be acquiring clinical-stage biotech company, Vitae, to boost its dermatology pipeline.

Last month, Allergan also bought privately held Akarna Therapeutics to add the latter’s lead product candidate AKN-083, a preclinical-stage FXR agonist, being evaluated for the treatment of NASH. Allergan also added the lead gene therapy development program RST-001 of privately held, clinical-stage biotechnology company RetroSense Therapeutics to its eye care pipeline last month.

In-licensing activities and collaborations for the development of pipeline candidates have also increased significantly. Several pharma companies are focusing on in-licensing, mid-to-late stage pipeline candidates that look promising, instead of developing a product from scratch, which involves a lot of funds and time.

Small biotech companies are open to such deals as most of them find it challenging to raise cash, thereby facing difficulty in surviving and continuing with the development of promising pipeline candidates. Therefore, it makes sense to seek deals with pharma companies sitting on huge piles of cash.

Merger and acquisitions, especially small bolt-on acquisitions, as well as aggressive in-licensing activities and collaborations are expected to increase, going forward. This in turn puts the spotlight on small cap biotech stocks.

Biotech companies with new therapies or interesting pipeline candidates can be strong takeover targets.

Here we have narrowed down the list of choices by focusing on five stocks with a favorable Zacks Rank of #1 (Strong Buy) or #2 (Buy). Also, these are small cap biotech companies with a market cap of less than $1 billion. These stocks are well positioned in today’s market environment and could see considerable upside riding on the aforementioned trends.

VIVUS Inc. ( NASDAQ:(VVUS - Free Report) - Free Report )

Mountain View, CA-based VIVUS, Inc. focuses on developing compounds to treat obesity, sleep apnea, diabetes and sexual health. VIVUS’ key product, Qsymia, targets the highly lucrative obesity market with huge commercial potential.

VIVUS delivered positive earnings surprises in three of the past four quarters, with an average beat of 39.88%. Its loss estimates for 2016 and 2017 have narrowed over the past 60 days. The company’s share price has increased 13% year to date. Currently, VIVUS sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here .

Geron Corporation ( NASDAQ:(GERN - Free Report) - Free Report )

Menlo Park, CA-based biopharmaceutical company, Geron Corporation focuses on the development of first-in-class therapeutic products for the treatment of cancer. Geron's product development programs are based on its patented core technology, telomerase, which represents significant commercial opportunity. The successful development of products that target telomeres could very well change the treatment paradigm for several diseases including oncology, which represents huge commercial potential.

Geron, which carries a Zacks Rank #1, delivered positive earnings surprises in each of the past four quarters, with an average beat of 20.78%. Its loss estimates for 2016 have narrowed from 26 cents to 24 cents in the past 60 days.

Achillion Pharmaceuticals, Inc. ( NASDAQ:(ACHN - Free Report) - Free Report )

Achillion Pharmaceuticals is a development-stage company, focused on the development of potent and specific complement factor D inhibitors for rare and other diseases. Achillion has out-licensed its HCV portfolio to Janssen, a Johnson & Johnson company.

Currently, Achillion holds Zacks Rank #1. It delivered positive earnings surprises in all the past four quarters, with an average beat of 364.79%. Its loss estimates for 2016 have narrowed from 66 cents to 62 cents in the past 60 days.

Anika Therapeutics Inc ( NASDAQ:(ANIK - Free Report) - Free Report )

Anika Therapeutics makes therapeutic products and devices that promote the repair, protection and healing of bone, cartilage and soft tissues. Its products are based on hyaluronic acid, a naturally occurring, biocompatible polymer found in the body. The stock carries a Zacks Rank #1.

Anika Therapeutics’ earnings estimates for 2016 and 2017 have increased a respective 9.5% and 11.5% over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, with an average beat of 42.19%. Its share price has jumped 25% year to date.

ANI Pharmaceuticals, Inc. ( NASDAQ:(ANIP - Free Report) - Free Report )

This Zacks Rank #2 specialty pharmaceutical company witnessed an increase of 9.5% and 4.7% in its earnings estimates for 2016 and 2017, respectively, in the last 60 days. It surpassed earnings estimates twice in the last four quarters, bringing the average positive surprise to 46.85%. The company’s share price has surged 50.6% year to date.

Now See Our Private Investment Ideas

While the above ideas are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trades >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on VVUS - FREE

Get the full Report on GERN - FREE

Get the full Report on ACHN - FREE

Get the full Report on ANIK - FREE

Get the full Report on ANIP - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.

This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.